Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastomaPaul M. Clément, Martin J. van den Bent, Jim Looman et al.|European Journal of Cancer|2021Cited by 20
LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410Martin J. van den Bent, Vassilis Golfinopoulos, Marica Eoli et al.|Neuro-Oncology|2017Cited by 14
Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406).Martin J. van den Bent, Vassilis Golfinopoulos, Pim J. French et al.|Journal of Clinical Oncology|2018Cited by 14
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastomaMartin J. van den Bent, Vassilis Golfinopoulos, Marica Eoli et al.|Neuro-Oncology|2020Cited by 8
ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX–M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406Martin J. van den Bent, Vassilis Golfinopoulos, Pim J. French et al.|Neuro-Oncology|2018Cited by 4